Clinical Trial Update: Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating decitabine in patients with advanced refractory solid tumors or lymphomas; study status terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Cancer
• Lymphoma
• Solid Tumor

Drugs mentioned

• Dacogen (decitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: TERMINATED